AfroCentric reports 42.77% increase in HEPS to end-June

Healthcare group CEO Karsten Wellner says acquisitions will be in higher-growth economies

The healthcare group is looking to buy complementary businesses in 2018 with headline earnings up 91% in the year to June

Pharmaceutical company says the deal will allow it to diversify its product offering, as there is very little overlap between the two companies’ ...

The company still has much to prove before its liquidity levels showed up on the counter, says analyst

Novel cell therapies that reprogramme a body’s immune system to attack tumours are just now coming of age, but their developers are already bracing for ...

The main reason for the increase was that the previous year included one-off costs related to a UK acquisition and rebranding

The pharmaceutical company says the boost in earnings per share was as a result of the once-off negative effect in the comparative period

The after-tax loss was R48m, compared with R15.7m in 2016

The group has day-hospitals in SA and Australia, and says the losses are ‘as anticipated’

The life-saving drug is not yet widely available to state patients but some healthcare facilities are buying it at a lower cost, says the Swiss pharma giant

The patent for Prevnar 13 allows Pfizer to sell it exclusively in India until 2026, which is a blow to poorer nations

The company, like the hospital industry, has been under pressure for some time

About 100 manufacturers, importers and distributors have applied for licences ahead of the August 23 deadline

The group’s share price has plunged 22.45% in the past six months as fewer employed workers contribute to medical schemes

Bonitas has been chosen for Commed members to ensure their benefits are not compromised, Council for Medical Schemes registrar Sipho Kabane says